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Abstract
Background: Perinatal depression (PND) has an overall estimated prevalence of roughly 12 %. Untreated PND has
significant negative consequences not only on the health of the mothers, but also on the physical, emotional and
cognitive development of their children. No certain risk factors are known to predict PND and no completely safe
drug treatments are available during pregnancy and breastfeeding. Sleep and depression are strongly related to
each other because of a solid reciprocal causal relationship. Bright light therapy (BLT) is a well-tested and safe
treatment, effective in both depression and circadian/sleep disorders.
Methods: In a 3-year longitudinal, observational, multicentre study, about 500 women will be recruited and
followed-up from early pregnancy (10–15 gestational week) until 12 months after delivery. The primary aim of the
present study is to systematically explore and characterize risk factors for PND by prospective sleep assessment
(using wrist actigraphy, polysomnography and various sleep questionnaires) and bloodbased analysis of potential
markers during the perinatal period (Life-ON study). Secondary aims are to explore the relationship between
specific genetic polymorphisms and PND (substudy Life-ON1), to investigate the effectiveness of BLT in treating
PND (substudy Life-ON2) and to test whether a short term trial of BLT during pregnancy can prevent PND
(substudy Life-ON3).
Discussion: The characterization of specific predictive and risk factors for PND may substantially contribute to
improve preventive medical and social strategies for the affected women. The study results are expected to
promote a better understanding of the relationship between sleep disorders and the development of PND and to
confirm, in a large sample of women, the safety and efficacy of BLT both in prevention and treatment of PND.
Trial registration: ClinicalTrials.gov NCT02664467. Registered 13 January 2016.
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Background
Perinatal depression (PND) refers to the onset of major
depression during pregnancy (antenatal depression, AD)
and up to 12 months after delivery (postpartum depres-
sion, PPD). The estimated prevalence of PND is roughly
12 % [1] with a three-fold increase in incidence of de-
pression during the postpartum period compared to nul-
lipara [2]. Up to 80 % of women in the postpartum
period report some kind of depressive symptoms, which
range from a mild and transient form of sadness that is
frequently termed “baby blues” to full diagnoses of major
depression [3]. The Diagnostic and Statistical Manual of
Mental Disorders, 4th edition text-revised (DSM-IV-TR)
defined a specific subtype of major depressive disorder
as post-partum depression (PPD) when the onset of the
depressive episode occurs within 4 weeks after delivery
[4]. Indeed, the risk of depression in puerperal women
remains high through the first postpartum year [5], and
in around 50 % of the cases the onset of depression oc-
curs already during pregnancy. Based on this, the above
mentioned, wider definition of perinatal depression
(PND) has been adopted. The revised fifth edition of
DSM (DSM-V) does not recognise this entity as a separ-
ate diagnosis, but as a specifier of major depression by
using the term of “perinatal-onset or peripartum”, where
a woman has to meet the criteria for major depressive
episode with an onset in pregnancy or within 4 weeks of
delivery [6]. An unrecognized or an untreated PND in-
creases the risk of preterm delivery [7], smoking and sub-
stance use, shortening of breastfeeding [8], abusive
behaviour toward children, suicide [9], negative effects on
the relationship with the partner and cognitive problems
in infants [10]. A significantly higher mean mother-infant
daily cost was estimated by the British health system for
women with PND compared to women without PND
[11]. The absence of defined objective markers for PND
diagnosis, which is purely based on the clinical interview
and therefore examiner-dependent, is a significant limit to
unequivocal and early recognition of the disease. More-
over, to date, except for a history of depression or positive
familiar psychiatric history, no certain medical risk factors
are known to predict PND [12]. With the exception of
theoretical abnormalities in hypothalamic-pituitary-
adrenal axis activity and possible genetic risk factors that
are shared with a variety of psychiatric disorders, the etio-
pathogenesis of PND is still unknown. Once PND is rec-
ognized, no definitely safe pharmacologic treatments are
available during pregnancy and breastfeeding [13], and the
concurrent lack of preventive therapies exposes the health
of women and children to the PND related risks. Placebo-
controlled, randomized trials of antidepressant substances
in this population are lacking, and the methodological
flaws of available studies limit the generalizability of the
findings. A large meta-analysis recently concluded that
evidence over benefits/harms of available compounds can-
not adequately support informed decisions about the
treatment of PND [14]. Furthermore, teratogenicity con-
cerns commonly influence women’s acceptance of poten-
tially effective treatments. Therefore, a safe and effective
treatment remains an urgent, currently unmet, clinical
need.
The main aims of the present project are to explore
the field of sleep in search of possible causative or pre-
dictive markers of PND and to test the safety and effi-
cacy of bright light treatment (BLT) in PND. Sleep and
depression are strongly related to each other with a solid
reciprocal causal connection. There are several lines of
evidence that suggest a pivotal role of perinatal-related
sleep changes in the genesis of depression during this
period. Of special importance for the present project is
the consistent finding that specific sleep abnormalities
are already observed in never-depressed high-risk pro-
bands and predict the subsequent onset of depression
[15, 16].
BLT is a well-tested and safe therapy, which is effective
in both depression [17, 18] and circadian/sleep disorders
[19]. BLT is currently the treatment of choice for sea-
sonal depression [20]. So far, the application of BLT in
the treatment of PND has been limited but with overall
positive results. BLT for 3 to 6 weeks improved depres-
sion and appeared to be a safe therapy for females dur-
ing pregnancy and postpartum in few small open label
trials [21–26].
Sleep disorder, chronobiology and depression
A bidirectional relationship between sleep disorders and
depression is well established. Affective disorders, such
as major depression, are strongly associated with disrup-
tion in circadian rhythms, as demonstrated by the iden-
tification of polymorphisms in specific circadian genes
that are associated with these disorders. The complex
interaction between circadian genes and mood-related
neurotransmitter systems, in addition to the impact of
chronic stress on rhythms, are considered the mecha-
nisms underlying this relationship [27]. Further than
sleep, other circadian rhythms like hormone secretion
(cortisol, prolactin, growth hormone, cortisol), body
temperature and cognitive performance are impaired in
patients affected by depression [28]. Sleep deprivation
has been demonstrated to be the strongest therapy in
the acute phase of depression [29].
Therefore, it is not surprising that the DSM-V includes
changes in sleep duration (insomnia or hypersomnia)
among the diagnostic criteria for major depressive dis-
order as an additional symptom. Mood disorders are
commonly associated with subjective complaints of in-
somnia (difficulty falling asleep, restless sleep, early
morning awakening, decrease sleep duration); sleep is
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less deep and refreshing and a high prevalence of dis-
turbing dreams is reported by depressed patients.
The nocturnal recording of sleep (polysomnography -
PSG) provides reliable biomarkers of depression. Object-
ive sleep markers in depressed patients concern sleep dis-
turbances such as prolonged sleep latency (SL), increased
wake after sleep onset (WASO), increased early morning
wake time, decreased total sleep time (TST), decreased
sleep efficiency (SE = percentage of sleep on the total bed
time), decreased slow waves sleep (SWS), decreased REM
sleep latency, increased REM amount [30]. Nevertheless,
mood disorders are also commonly found in patients af-
fected by sleep disorders (i.e. insomnia [31], sleep apnoea
[32], and restless legs syndrome [33]).
Sleep disorders during pregnancy and perinatal
depression
Sleep abnormalities are highly prevalent during preg-
nancy [34]. In the first trimester of pregnancy women
often complain about fatigue and excessive daytime
sleepiness. In the third trimester there is a high preva-
lence of insomnia, sleep related breathing disorders (i.e.
obstructive sleep apnea syndrome) [35, 36], and restless
legs syndrome (RLS) [37]. Several studies demonstrated
a solid association between poor sleep quality, sleep dis-
orders and post-partum mental disorders such as psych-
osis, anxiety and overall depression [38]. The occurrence
of RLS during pregnancy is related to an increased risk
of PND [39]. These findings call for a comprehensive
evaluation of sleep and related disorders during preg-
nancy, suggesting sleep as a black box hiding possible
precious candidate features for PND prediction. An early
recognition of these sleep-related features during preg-
nancy would be highly valuable for an accompanying
preventive or psychoeducational intervention in affected
women, avoiding potential devastating maternal and
foetal consequences.
Bright light treatment for perinatal depression
The treatments of choice for major depression are anti-
depressant drugs. However, no drugs belonging to anti-
depressant classes (tricyclic, SSRI, SNRI) are unequivocally
safe during pregnancy and breastfeeding [13]. BLT is cur-
rently the treatment of choice for seasonal affective disor-
ders [20, 40] and also well-known as an effective treatment
for non-seasonal depression [41]. Few side effects related to
this treatment are reported and include jumpiness/jitteri-
ness, nausea and headache [42]. In a cohort of untreated
patients with normal ocular-retinal status, ophthalmologic
evaluations did not document any acute light-induced path-
ology or long-term sequelae [43].
There is increasing evidence that depression is associated
with misalignment of the circadian rhythm and that the
well-established effects of BLT on circadian synchronization
are associated with its antidepressant effects [44]. BLT pro-
motes the resynchronization of the suprachiasmatic nu-
cleus (SCN), the master circadian pacemaker, which is
impaired in depressed patients. The firing of SCN neurons
is modulated by an endogenous rhythm and by the re-
sponse to photic/non-photic information received from af-
ferent inputs, which mainly depends on the day-night cycle
[44]. The effect of light on the SCN is mediated by the mul-
tisynaptic circuit of the retino-hypotalamic tract, which
connects retinal photoreceptors (especially the retinal gan-
glion cells containing melanopsin) to the anterior hypothal-
amus where the SCN is located [45].
The antidepressant effect of BLT is also mediated by
biogenic amines, especially serotonin. In patients suc-
cessfully treated with BLT and in remission, depletion of
tryptophan, the amino acid precursor of serotonin, re-
versed the effects of BLT on mood [46, 47]. In addition,
the mood lowering effect of tryptophan depletion is
blocked under bright light conditions [48] again support-
ing the notion that BLT affects serotonergic neurotrans-
mission. Since alterations in tryptophan [49] and the
hypothalamic pituitary adrenal (HPA) axis activity [50, 51]
during pregnancy have been implicated in serotonin dys-
regulation and PND, this provides a possible rationale for
the application of BLT in PND. As detailed above, a fur-
ther rationale is the expectation that BLT’s positive effects
on sleep disturbances and alertness during the perinatal
period will indirectly improve depressive symptoms.
Because of its well-established antidepressant efficacy
and low side-effect profile, the benefit of BLT on mood
disorders during pregnancy and post-natal period has
been already investigated in small pioneering open label
trials [21–25] (Table 1). Overall, 3- to 6-week morning
BLT for 30 to 60 min improved several depression scores
by close to 50 %. Moreover, in these trials BLT appeared
to be a safe treatment for females during pregnancy and
puerperium. These positive results pave the way to lar-
ger randomized trials with the aim of determining the
effectiveness of BLT in perinatal depression, and the
safety and feasibility of this therapy [26].
Methods/design
Working hypothesis and outcomes
As already mentioned, PND is highly prevalent and is
associated with maternal and foetal negative outcomes;
however, its pathophysiology is still largely unknown and
besides an increased risk for females with prior depres-
sion, no clear risk profile has been yet established. Sleep
abnormalities have higher prevalence during pregnancy
compared to the general population, but it is not clear
whether they could predict the development of PND.
Therefore, an increased knowledge of antecedents and
risk factors will provide important information about
causes, prevention, and treatment of PND. At the same
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time, since antidepressant drugs are not definitely safe
during pregnancy and breastfeeding, there is an urgent
need for safe and efficacious treatments of PND with
minimal side effects. Hence, the theory behind the pro-
ject is that the sleep structure during pregnancy contains
essential information for the early identification of
women who will develop PND. Second, given its efficacy
in depression not related to pregnancy, we reason that
BLT might be an easy, home-based, self-administered
and safe treatment option to prevent PND in women
during the early stages of pregnancy and to treat an
already established PND during pregnancy and the
puerperium.
Null hypothesis
Neither subjective or polysomnographic sleep features
or sleep disorders can be related to development of
PND. BLT is not effective in preventing or treating PND.
Specific aims
Primary aim
To systematically and prospectively explore sleep and
sleep-related parameters, as well as mood changes
during pregnancy and the postpartum in order to
identify reliable, potential early diagnostic markers of
PND (Life-ON study).
Secondary aims
1) To investigate the relationship between specific
genetic polymorphisms and the development of
depression during pregnancy and the postpartum
(substudy Life-ON 1)
2) To investigate the effectiveness of BLT in treating
PND (substudy Life-ON 2).
3) To test whether a short term trial by BLT in non-
depressed pregnant women can prevent the onset of
PND (substudy Life-ON 3)
Description of the study
The Life-ON Project is a prospective, both observational
and interventional, multicentre [three sleep centres in
Northern Italy (Bologna, Milan, Turin) and one in
Southern Switzerland (Lugano)], non-profit, without
medicines, cohort study, which will include about 500
women, who will be longitudinally followed from early
pregnancy (10–15 gestational week) until 12 months
after delivery. Pregnant females attending the outpatient
clinics of the involved centres and who gave voluntary
written informed consent to participate in the study
(Life-ON) will be included consecutively. Inclusion and
exclusion criteria are listed in Table 2.
Participating women will undergo scheduled clinical
examinations by a multidisciplinary team including a gy-
naecologist and/or obstetrician, a psychologist or psych-
iatrist and a neurologist expert in sleep disorders.
During the periodic follow-up visits, medical/gynaeco-
logical, psychological and sleep will be assessed by struc-
tured interviews and validated scales and questionnaires
(Table 3).
Pregnant women, who will have accepted to partici-
pate in the main observational Life-ON study, will also
Table 1 Published studies on the efficacy of bright light therapy in perinatal depression. Adapted from Crowley et Youngstedt [26]
Study Subjects (n),
gestational
week (w)
Design, patients
vs. controls (n),
duration (w)
Bright light treatment Outcomes Adverse effects
Antenatal depression
Oren et al.
2002 [23]
n = 16 OL 10,000 lux, 60 min morning
(10 min after awakening)
SIGH-SAD decreased by 49 % after 3 w,
by 59 % after 5 w
2 patients experienced
nausea
23 ± 7 w 3–5 w
Epperson
2004 [22]
n = 10 R PC PG 7,000 lux vs. 500 lux, 60 min
morning (10 min after
awakening)
no difference vs. placebo, SIGH-SAD
improved in both groups by 45 %
Irritable hypomania in one
subject resolved after
reduction of light exposure20 ± 8 w 5 vs. 5
5 w
Wirz-
Justice et
al. 2011
[25]
n = 26 R PC DB PG 7,000 lux vs. 70 lux red
light, 60 min morning
(10 min after awakening)
significant greater improvement with
active treatment (SIGH-HADS 58 % vs.
41 %, HDRS 64 % vs. 38 %)
No clinically meaningful side
effects
̴25 w 16 vs. 10
5 w
Postpartum depression
Corral
2000 [21]
n = 2 OL 10,000 lux 30 min morning
(7:00–9:30)
HDRS decreased by 38 and 43 % no adverse side effects
4 w
Corral
2007 [24]
n = 15 R PC PG 10,000 lux vs. 600 lux red
light, 30 min morning
(7:00–9:00)
no difference vs. placebo, SIGH-SAD
improved in both groups by 49 %
no adverse side effects
10 vs. 5
5 w
Legend: OL open-label, R randomized, PC placebo-controlled, PG parallel group, DB double-blind
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be asked to additionally and voluntarily take in part in
the Life-ON 1 substudy (genetic investigation). The sub-
study Life-ON 2 will be proposed to women who de-
velop PND during pregnancy or during the 9 months’
period after delivery. A random population of non-
depressed pregnant women will be asked to participate
in the preventive BLT trial Life-ON 3 (substudy). A spe-
cific dedicated written informed consent is necessary to
participate in each of the above mentioned substudy,
and woman can withdraw their consent at any time
(Fig. 1).
Concomitant drugs
The use of any drug prescribed in the normal clinical
pathway will be allowed during the study.
Experimental design – Life-ON study
Life-ON is an observational, longitudinal study, which
will systematically and prospectively explore sleep and
sleep-related parameters during pregnancy and their cor-
relation with the onset of PND. The expected outcome
is to identify reliable, potential, early diagnostic markers
of PND.
Demographic and gynaecological/obstetrical data
will be collected for all women included in the study.
Mood, sleep quality and disorders, and other bio-
markers will be assessed at regular intervals during
the perinatal period, until 12 months postpartum, in
all participants (Additional file 1: Table S1a).
Sleep investigations will include an interview with a
sleep expert to determine lifetime and current sleep dis-
turbances, supplemented with questionnaires assessing
sleep quality, insomnia, daytime sleepiness, circadian
chronotype, sleep-related movement disorders and para-
somnias. Unattended ambulatory polysomnography
(PSG) will be conducted in all participants between the
23th and 25th gestational week. This will include elec-
troencephalogram (F3, C3,O1 referenced to the contra-
lateral mastoid, M2), bilateral electro-oculogram, surface
electromyogram of submentalis muscle and bilateral
tibialis anterior muscles, electrocardiogram and sleep re-
spiratory parameters (nasal air flow, thoracic and ab-
dominal respiratory effort, oxygen saturation).
Sleep will be scored by a sleep specialist according to
the international guidelines [52]. The rest/activity cycles
during pregnancy and postpartum will be assessed by 7-
days actigraphic recordings repeated for 3 times: be-
tween the 23th and 25th gestational week, around the
3rd (between 90 and 105 days) and between the 11th
and the 12th month after delivery.
All participants will undergo a psychiatric and psycho-
logical evaluation, including semi-structured interviews
and questionnaires for screening depression, stressful life
events and selected personality traits. Depressive symp-
toms will be assessed at the time of study inclusion and
approximately every 3 months until the 12th month post-
partum with a higher sampling rate (every two weeks)
during the two postpartum months; the diagnosis of PND
will be always established using structured clinical inter-
views conducted by staff psychologists/psychiatrists.
Experimental design – substudy Life-ON 1
Life-ON 1 substudy consists in a genetic test on a blood
sample taken during the 23rd-25th gestational week, with
the aim to identify possible specific genetic polymorphisms,
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Age 18–45 years
• Free of any major medical
condition
• Normal ocular function
• Gestational age between 10 to
15 weeks at time of screening
• Written informed consent
• Diagnosis of bipolar I or II disorder
(DSM-5)
• Recent history (less than 6 months)
or current major depression or an
Edinburgh Postnatal Depression
Scale (EPDS) score > 12 at time of
inclusion
• Any psychotic episode, substance
abuse, recent history of suicide
attempt (less than 12 months)
• Use of antidepressants or other
pharmacologic treatments for
depression in the last 6 months
• Intrauterine fetal death
Table 3 Psychiatric and sleep assessment tools
Psychiatric assessment tools
• MINI-International Neuropsychiatric Interview (MINI), clinician rated [53]
• MINI-International Neuropsychiatric Interview Plus (MINI Plus), clinician
rated
• Edinburgh Postnatal Depression Scale (EPDS), self-administered
(depression > 12) [54]
• Visual Analog Scale for depression (VAS), self-administered (ranging
between 0 and 10) [55]
• Hamilton Depression Rating Scale - 21 items (HDRS-21), clinician-rated
(14–18 =moderate depression, 19–22 = severe depression, ≥ 23 = very
severe depression) [56]
• Montgomery-Asberg Depression Rating Scale (MADRS), clinician-rated
(normal 0–6; mild depression 7–19; moderate depression 20–34; severe
depression >34) [57]
• Temperament and Character Inventory (TCI), self-administered [58]
• Interview for Recent Life Events (IRLE), self-administered [59]
Sleep assessment tools
• Pittsburgh Sleep Quality Index (PSQI), self-administered (good sleeper
<5; poor sleeper ≥5) [60]
• Insomnia Severity Index (ISI), self-administered [normal ≤7; sub thresh-
old insomnia 8–14; clinical insomnia (moderate severity) 15–21; clinical
insomnia (severe) 22–28] [61]
• Epworth Sleepiness Scale (ESS), self-administered (normal <10; patho-
logical≥ 10) [62]
• RLS interview (5 criteria), clinician rated [63] and the International RLS
Study Group Rating Scale (if RLS diagnosed) [64]
• Munich Parasomnia Screening (MUPS), self-administered [65]
• Morningness-Eveningness Questionnaire (MEQ), self-administered (16–30
“definite evening types”, 31–41 “moderate evening types”, 42–58 “inter-
mediate types”, 59–69 “moderate morning types”, 70–86 “definite morning
types”) [66]
• One night of home polysomnography (PSG)
• Wrist Actigraphy (7-days of consecutive home recording)
Baiardi et al. BMC Psychiatry  (2016) 16:374 Page 5 of 10
that may be associated with PND. Part of the blood samples
taken at inclusion will be processed and stored in a bio-
bank for future use.
Experimental design – substudy Life-ON 2
Life-ON 2 is a longitudinal and interventional trial,
which will investigate the effectiveness of BLT in treating
PND. Women with minor or major depression, diag-
nosed by a psychiatric interview or with an EPDS score
>12 at any time from study inclusion to 9 months post-
partum, will be invited to participate in the randomized-
controlled BLT trial. Participants will be randomised on
a 1:1 basis to receive 6 weeks of morning BLT or dim
light placebo. The trial will be single blind. Subjects will
be asked to maintain their habitual bedtime and wake-
up schedule, and to begin the light treatment within
20 min of habitual wake-up time. Subjects will be
instructed to sit in front of the light box (Philips Energy
Up HF 3419) at a specified distance (around 30 cm) and
to receive an active light dose (10’000 lux) or placebo
dim light (50 lux) for ½ hour. Safety will be monitored
with the self-report version of the Systematic Assess-
ment of Treatment Emergent Effects (SAFTEE). Simi-
larly to Life-ON, all participants will be followed up
until 12 months postpartum.
Experimental design – substudy Life-ON 3
Life-ON 3 is a longitudinal and interventional trial, in
non-depressed women, which will investigate the effect-
iveness of BLT during pregnancy in preventing PND. A
subsample of 80 subjects without depression will be ran-
domly, consecutively recruited to receive 6-week open-
label BLT during the third trimester of pregnancy. The
selected participants will receive ½ hour of morning BLT
(10’000 lux, Philips Energy Up HF 3419) for 6 weeks.
Subjects will be asked to maintain their habitual bedtime
and wake-up schedule, and BLT is planned to commence
within 20 min of habitual wake-up time. Safety will be
Fig. 1 Flowchart of the study design. Legend: D: depression; M: month; ND: no depression; PND: perinatal depression; PPD:
postpartum depression
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monitored with the Systematic Assessment of Treatment
Emergent Effects (SAFTEE). All participants will be
followed-up until 12 months postpartum and the main
outcome will be the incidence of postpartum depression
in subjects receiving BLT compared to subjects with no
treatment.
Safety assessment
The safety assessment will consist of monitoring and re-
cording of Adverse Reactions (ADRs) and Serious Adverse
Event (SAE) only for substudies involving treatment with
BLT.
Determination of sample size
This prospective, longitudinal cohort study will include
500 pregnant females. Given that we consecutively in-
clude participants, we judge this sample size as sufficient
to generate estimates for the prevalence of perinatal de-
pression, sleep disturbances, and sleep disorders during
pregnancy and postpartum. Based on a meta-analysis of
prevalence and incidence studies we expect the cumula-
tive incidence of minor and major depression during late
pregnancy and postpartum to be at least 20 % (n = 100).
Taking into consideration that we plan to include 80 fe-
males in a trial of light treatment for the prevention of
postpartum depression, we expect that approximately
300 females will be symptom free, while 100 to 150 fe-
males will experience minor or major depression during
the perinatal period. For the study of risk factors in-
volved into the development of perinatal depression, our
sample size will enable the detection of small to moder-
ate effects (d > 0.3) with an adequate statistical power
(≥80 %).
For the Life-ON study no significance threshold a
priori is considered.
The main outcomes of Life-ON 2 will be the change
of depressive symptoms, response and remission rates
after 6-week bright light treatment versus placebo. Based
on a previous meta-analysis we expect that the preva-
lence of depression during the perinatal period will be at
least 25 %, which would qualify 125 participants for in-
clusion in the treatment trial. From our previous experi-
ences we anticipate an attrition rate of 25 % for reasons
of refusal, non-compliance, or necessity for additional/
alternative treatment. A conservative estimate would,
therefore, be that 80 females will complete the treatment
trial. At the same time, weekly monitoring is expected to
increase compliance and reduce attrition and the avail-
able data suggests that prolongation of the treatment
duration to 6 weeks will increase the bright light versus
placebo difference. Our conservatively planned sample
size (40 versus 40) will enable us to demonstrate
medium effects (d >0.56) with a one-side error level of
0.05 and adequate statistical power (≥80 %).
Concerning the substudy Life-ON 3, previous meta-
analyses have estimated an incidence of 15 to 49 % for
the onset of minor and major depression during a
12 months’ postpartum period. Our sample size calcula-
tion is based on an assumed incidence of 20 % in fe-
males receiving no treatment and we expect this
incidence to be reduced to 5 % in females receiving
bright light treatment during late pregnancy. With a
planned allocation ratio of 1:3 and a one-sided alpha
level of 0.05, comparison of 43 treated females to 172
untreated subjects will yield an adequate statistical
power (≥80 %). Assuming an even lower incidence of
15 % in untreated subjects, sample size calculations indi-
cate that inclusion of 79 vs. 314 subjects will be needed
to demonstrate a reduced incidence (5 %) with adequate
statistical power. We therefore plan to block-randomise
consecutive participants on a 1:3 basis to BTL versus no
treatment until 80 participants have received active light
treatment.
Statistical analyses
Standard parametric or non-parametric statistical tests
will be employed to explore differences between females
with onset of depression to those remaining symptom
free. To take full advantage of the longitudinal study de-
sign, generalized mixed modelling will be employed to
test whether sleep-related and other fixed or variable
markers can predict the onset of perinatal depression,
possibly in a time-associated manner. The evaluation of
BLT effectiveness for perinatal depression should take
into account that this therapy will be applied at different
times during the perinatal period; therefore, this will be
included as a covariate in the ANCOVA (continuous
data) and logistic regression analyses (dichotomous data,
proportions). Regarding the efficacy of BLT in preven-
tion of post-partum depression we will use logistic re-
gression analysis to compare incidence rates between the
group of not-depressed patients who received light ther-
apy during pregnancy versus untreated subjects. For all
analyses p values < 0.05 will be considered significant.
The statistical analysis will be performed using a dedi-
cated software (SPSS, IL, USA).
Discussion
The presented project aims to address several questions
concerning PND, including epidemiology, pathophysi-
ology, prevention and treatment. It may substantially con-
tribute to a better knowledge of the relationship between
sleep disorders and PND, as well as of the feasibility, safety
and efficacy of BLT both in prevention and treatment of
depression during pregnancy and the postpartum period.
The characterization of specific risk factors for PND will
critically contribute to the development of preventive
medical and social strategies for the affected women and
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alert the healthcare community to this relevant and fre-
quent mental health problem. Finally, we expect that our
research will significantly contribute to improve care and
treatment for women during and after pregnancy and ul-
timately to the long-term wellbeing of mothers, children
and their families.
Additional file
Additional file 1: Table S1a Schedule of assessments. MINI: MINI
International Neuropsychiatric Interview; MINI Plus: MINI International
Neuropsychiatric Interview Plus; EPDS: Edinburgh Postnatal Depression
Scale; VAS: Visual Analog Scale; HDRS-21: Hamilton Depression Rating
Scale – 21 items (during trial also on days 0 – 21 – 42 of treatment);
MADRS: Montgomery-Asberg Depression Rating Scale (during trial also
on days 0 – 21 – 42 of treatment); TCI: Temperament and Character
Inventory; IRLE: Interview for Recent Life Events; PSQI: Pittsburgh Sleep
Quality Index; ISI: Insomnia Severity Index; ESS: Epworth Sleepiness Scale;
RLS: Retless Legs Syndrome; MEQ: Morningness-Eveningness Questionnaire;
PSG: Polisomnography; SAFTEE: Systematic Assessment of Treatment Emer-
gent Effects (during trial after 3 and 7 weeks of treatment). (DOCX 30 kb)
Abbreviations
BLT: Bright light therapy; CRF: Case report form; ECG: Electrocardiogram;
EEG: Electroencephalography; EMG: Electromyography;
EOG: Electrooculography; EPDS: Edinburgh perinatal depression scale;
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